Researchers at the Johns Hopkins Bloomberg School of Public Health have recently uncovered a significant gap in compliance with the Food and Drug Administration’s (FDA) guidance on testing pulse oximeters across diverse skin tones. Despite an increase since the FDA issued its guidance in 2013, only a modest number of manufacturers have adapted their testing protocols to include individuals with a range of skin pigmentations. This development is particularly concerning given that pulse oximeters, devices intended to measure blood oxygen levels by passing light through the skin, have been shown to yield less accurate results for individuals with darker skin. The potential implications of this oversight are significant, as undetected low blood oxygen levels could lead to misdiagnosis and delayed treatment for vulnerable populations.
The FDA’s recommendations arose following a growing body of evidence suggesting that pulse oximeter devices could misrepresent blood-oxygen saturation levels in patients with darker skin tones. This discrepancy is alarming, especially considering that these devices have become crucial tools for both clinical and at-home monitoring of patients, particularly amid the COVID-19 pandemic. The study indicates a concerning trend in medical device testing and regulatory compliance, highlighting the longstanding issues related to racial and ethnic disparities in healthcare technology.
When analyzing the FDA clearance summaries from pulse oximeter manufacturers both before and after the 2013 guidance, it was revealed that only a quarter of clearance summaries post-2016 included any indication of adherence to the recommendations regarding diverse participant representation. Prior to the guidance, only 4.1% of summaries acknowledged the need for testing on subjects with varying skin tones. This illustrates that, while the FDA’s guidance had some influence, the implementation has been alarmingly slow.
The critical operational definition of "clearance" from the FDA refers to the process by which medical devices are permitted for use based on their similarity to already approved devices. Pulse oximeters, specifically those utilized for monitoring and medical decision-making, are subjected to this regulatory pathway. With the increase in purchasing and utilization of these devices during the pandemic, accurate testing and validation of their effectiveness across all demographic groups is now more pressing than ever.
In their research letter published online in JAMA, the authors underscore the limitations of relying solely on voluntary guidelines to resolve biases inherent in pulse oximetry. The lead author, Dr. Kadija Ferryman, posits that further collective action from various stakeholders, including manufacturers and healthcare organizations, is essential to address the systemic biases in pulse oximetric assessments effectively. The FDA’s recent efforts to bolster its guidelines are a crucial step, but they alone will not fully remedy the problem.
The researchers noted that, since the original guidance, there has been a modest statistical improvement in manufacturers recognizing the need for diverse participant pools in their testing. However, the majority of post-guidance clearance summaries still fail to include any relevant mention of skin tone considerations or the necessity of diverse testing groups. Moreover, many of the summaries containing such references did not utilize standardized language to assess skin tone variations, instead opting for generic descriptors that could obscure the granularity needed for accurate representation.
As pulse oximeters continue to be a staple in both clinical settings and for personal use, the importance of precise readings cannot be overstated. These devices are integral in diagnosing dangerous conditions that can result from low blood oxygen levels, such as respiratory distress or hypoxemia, making it critical that all populations benefit from their reliable use. Cultural competence is an ongoing challenge in medical technology development, and this study sheds light on the complexities surrounding effective health monitoring for culturally diverse populations.
With an eye towards the future, the research team advocates for the standardization of testing trials and clearer benchmarks regarding skin tone variation. The need for measurable, consistent practices in clinical devices is vital to ensuring that similar issues do not persist as new technologies are developed and brought to market. The ongoing dialogue within public health and bioethics sectors reveals a growing recognition of the intricate ties between technology, race, and health outcomes.
The FDA’s newly updated draft guidance—which is open for public comment until March—is an opportunity for stakeholders to engage in meaningful discourse regarding these issues. It invites input from a wide spectrum of voices, from patients to practitioners, ensuring that pulse oximeters serve the entirety of the population effectively. Addressing this "wicked problem" necessitates a collaborative effort, wherein all parties work towards inclusivity in medical technology testing.
In summary, while the FDA’s guidance marked a pivotal moment in addressing racial and ethnic bias in pulse oximetry, the study illuminates the fact that compliance remains inadequate. The inherent biases in healthcare technology are complex, but they must be systematically addressed to ensure equitable health outcomes for every individual, regardless of their skin tone. It is imperative that manufacturers, alongside regulatory bodies, prioritize diversifying their participant pools to enhance accuracy and promote greater patient safety.
As the healthcare landscape evolves, the responsibility falls on all stakeholders to ensure that disparities in technology do not correlate with disparities in care. Greater emphasis on inclusivity in medical testing and the rigorous application of guidelines will be essential in bridging the gaps present in healthcare delivery today. Achieving equity doesn’t end with the recognition of issues; it requires sustained efforts, accountability, and a commitment to systemic change in the healthcare system.
Subject of Research: Compliance with FDA guidance on pulse oximeter testing across diverse skin tones
Article Title: Pulse Oximeter Testing: Bridging the Gap in Racial and Ethnic Disparities
News Publication Date: December 30, 2023
Web References: JAMA Research Letter
References: Ferryman, K., et al. (2023). Adherence to FDA Guidance on Pulse Oximetry Testing Among Diverse Individuals, 1996–2024. JAMA.
Image Credits: N/A
Keywords: pulse oximeter, FDA, racial bias, health disparities, public health
